ArticleNeuro-oncology2020
Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas.
Article in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- The impact of COVID-19 on clinical outcomes in people undergoing neurosurgery: a systematic review and meta-analysis.Systematic reviews · 2023Pooled it
- Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development.International journal of radiation oncology, biology, physics · 2020Pooled it
- The impacts of the COVID-19 pandemic on IDH-wildtype glioblastoma survival: A Surveillance, Epidemiology, and End Results Analysis.Neuro-oncology practice · 2025Article
- Effects of the COVID-19 Pandemic on Everyday Neurosurgical Practice in Alsace, France: Lessons Learned, Current Perspectives, and Future Challenges-Preliminary Results of a Longitudinal Multicentric Study Registry.Medicina (Kaunas, Lithuania) · 2024Article
- Impact of the COVID-19 Pandemic on Incidence and Observed Survival of Malignant Brain Tumors in Belgium.Cancers · 2023Article
- Trends in frailty in brain tumor care during the COVID-19 pandemic in a nationwide hospital network in Germany.European geriatric medicine · 2023Observational
- Neurosurgical care for patients with high-grade gliomas during the coronavirus disease 2019 pandemic: Analysis of routine billing data of a German nationwide hospital network.Neuro-oncology practice · 2023Article
- Neuro-oncology in the crosshairs during the coronavirus disease 2019 pandemic.Neuro-oncology practice · 2023Article
- Tumor size, treatment patterns, and survival in neuro-oncology patients before and during the COVID-19 pandemic.Neurosurgical review · 2023Review
- Variation in postoperative outcomes of patients with intracranial tumors: insights from a prospective international cohort study during the COVID-19 pandemic.Neuro-oncology · 2023Article
- The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Survey About Specific Clinical Scenarios (Version 2023.1).Brain tumor research and treatment · 2023Article
- The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Recommendation Using the Delphi Method (Version 2023.1).Brain tumor research and treatment · 2023Article
- Treatment Patterns and Outcomes of Patients with Grade 4 Glioma Treated with Radiation during the COVID-19 Pandemic.Current oncology (Toronto, Ont.) · 2023Article
- Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations.Scientific reports · 2023Article
- Treatment of high-grade glioma patients during the COVID-19 pandemic: Impact on overall survival, tumor size and delay of treatment.PloS one · 2023Article
- COVID-19 hospitalization increases the risk of developing glioblastoma: a bidirectional Mendelian-randomization study.Frontiers in oncology · 2023Article
- Identification of Comorbidities, Genomic Associations, and Molecular Mechanisms for COVID-19 Using Bioinformatics Approaches.BioMed research international · 2023Article
- The impact of the COVID-19 pandemic on neuroimaging volume in New York City.The neuroradiology journal · 2022Article
- How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology?Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2022Review
- Observational
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors at 10 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBecause of the increased risk in cancer patients of developing complications caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), physicians have to balance the competing risks of the negative impact of the pandemic and the primary tumor. In this consensus statement, an international group of experts present mitigation strategies and treatment guidance for patients suffering from high grade gliomas (HGG) during the coronavirus disease 2019 (COVID-19) pandemic. METHOD /
results16 international experts in the treatment of HGG contributed to this consensus-based practice recommendation including neuro-oncologists, neurosurgeons, radiation -oncologists and a medical physicist. Generally, treatment of neuro-oncological patients cannot be significantly delayed and initiating therapy should not be outweighed by COVID-19. We present detailed interdisciplinary treatment strategies for molecular subgroups in two pandemic scenarios, a scale-up phase and a crisis phase.
conclusionThis practice recommendation presents a pragmatic framework and consensus-based mitigation strategies for the treatment of HGG patients during the SARS-CoV-2 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.